Welcome to our dedicated page for Armata Pharmctcl SEC filings (Ticker: ARMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Armata Pharmaceuticals filings document a NYSE American-listed biotechnology issuer developing bacteriophage-based product candidates for bacterial infections. Current reports on Form 8-K record FDA Fast Track and Qualified Infectious Disease Product designations for AP-SA02, financial-results releases, corporate updates, board appointments, annual meeting matters, and amendments to existing credit agreements with Innoviva Strategic Opportunities.
Proxy and governance filings cover board composition, director compensation, executive compensation disclosures, shareholder voting matters, and the company's common stock structure. Material-event filings also describe financing arrangements, warrant-related amendments, and furnished press releases tied to the AP-SA02 and AP-PA02 clinical-development platform.
Armata Pharmaceuticals’ major stockholder Innoviva reports beneficial ownership of 55,467,459 shares of common stock, or about 82.7% of the company. This total includes existing shares, warrants and shares issuable from a convertible loan.
As of this amendment, the Innoviva group directly owns 25,076,769 Armata shares, holds warrants for 10,653,847 additional shares, and can acquire 19,736,843 shares upon conversion of a prior convertible loan. The ownership percentage is calculated against 36,695,155 shares outstanding as of April 17, 2026.
The filing also discloses a new secured term loan: on May 12, 2026, Armata borrowed $25,000,000 from Innoviva Strategic Opportunities LLC under a credit agreement bearing 14.00% annual interest and maturing on January 11, 2029. This new debt is secured and is not convertible into Armata securities.
Armata Pharmaceuticals’ Q1 2026 report shows a net loss of $115.3M, largely driven by a $101.1M non‑cash loss from revaluing its related‑party Convertible Loan. Grant and award revenue was $0.8M, while research and development expenses reached $6.1M and general and administrative expenses were $3.5M.
Cash and cash equivalents were only $4.8M as of March 31, 2026, and management states this will not fund operations for 12 months, raising “substantial doubt” about the company’s ability to continue as a going concern. Total liabilities were $381.4M, including a fair‑value Convertible Loan of $254.9M and term debt of $88.0M.
The company relies heavily on financing from principal stockholder Innoviva via multiple high‑interest credit agreements and a $100M at‑the‑market equity program. It is preparing a Phase 3 superiority trial of IV phage candidate AP‑SA02 in complicated S. aureus bacteremia, supported by a Qualified Infectious Disease Product designation and up to $26.2M in non‑dilutive Department of Defense funding.
Armata Pharmaceuticals entered a new secured term loan agreement with Innoviva Strategic Opportunities for $25 million at a 14.0% annual interest rate, maturing on January 11, 2029, guaranteed by its domestic subsidiaries and secured by substantially all assets. The company also reported first quarter 2026 results: grant and award revenue was $0.8 million and research and development expenses were $6.1 million, reflecting continued investment in its AP‑SA02 bacteriophage program. Net loss widened sharply to $115.3 million, largely driven by a $101.1 million unfavorable change in the fair value of a Convertible Loan, while cash and cash equivalents declined to $4.8 million as of March 31, 2026. Armata highlighted FDA Qualified Infectious Disease Product and Fast Track Designation for AP‑SA02 and its goal to advance this candidate into a Phase 3 study in complicated S. aureus bacteremia.
Armata Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Fast Track Designation to AP-SA02, its intravenous multi-phage therapy for complicated Staphylococcus aureus bacteremia, including MSSA and MRSA. This status is intended for serious conditions with unmet medical need.
Fast Track allows more frequent FDA interactions, rolling review of a future Biologics License Application, and potential eligibility for Accelerated Approval and Priority Review if supported by clinical data. Armata plans to advance AP-SA02 into a Phase 3 superiority study in complicated bacteremia, anticipated to begin in the second half of 2026, following positive Phase 1b/2a diSArm study results partially backed by a $26.2 million Department of Defense award.
Armata Pharmaceuticals director Daniel B. Gilmer received a grant of stock options for 51,280 shares of common stock. The options have an exercise price of $12.92 per share and expire on April 24, 2036.
According to the terms, one-third of the underlying shares vest on each of the first, second, and third anniversaries of the April 24, 2026 grant date, as long as Gilmer continues to provide service through each vesting date. After this grant, he holds 51,280 stock options directly.
Armata Pharmaceuticals, Inc. filed an initial insider ownership report for Daniel B. Gilmer, who is identified as a director of the company. The Form 3 report shows no reported transactions, acquisitions, dispositions, or derivative positions at the time of this filing.
Armata Pharmaceuticals, Inc. is asking shareholders to vote at its June 11, 2026 annual meeting on four items: electing seven directors, approving executive pay on an advisory basis, choosing how often to hold future say‑on‑pay votes, and ratifying Ernst & Young as auditor for 2026.
Innoviva, Inc. beneficially owns 60,699,915 shares, or 83.9% of common stock outstanding as of April 17, 2026, giving it effective control. The proxy highlights Board independence, committee structures, and a separate independent Chair. It also notes Ernst & Young’s audit opinion for 2025 included substantial doubt about Armata’s ability to continue as a going concern due to recurring losses and negative operating cash flows.
For 2025, CEO Deborah Birx received total compensation of $1,249,889, Chief Business Officer Pierre Kyme received $791,575, and Principal Financial Officer David House received $554,770, combining salary, bonuses, equity awards and incentives. The Board recommends voting for all four proposals and an annual say‑on‑pay frequency.
Armata Pharmaceuticals, Inc. appointed Dr. Daniel B. Gilmer, 39, to its Board of Directors, effective April 24, 2026, to serve until the next annual shareholder meeting. He will receive the Company’s standard non-management director compensation, including a $40,000 annual cash retainer.
Dr. Gilmer is expected to receive a stock option to purchase 51,280 shares of common stock at the fair market value on the grant date, vesting in equal installments over three years under Armata’s 2016 Stock Incentive Plan. The Company also entered into a standard indemnity agreement with him and noted there are no related-party or Item 404(a) transactions.
Armata highlighted Dr. Gilmer’s extensive background at Pfizer, where he leads commercial quality across more than 50 U.S. brands and previously helped launch an FDA‑approved antiviral and diagnostics portfolio. His experience in antimicrobial resistance and bacteriophage therapeutics aligns with Armata’s late clinical-stage phage-based pipeline.
Armata Pharmaceuticals, Inc. has scheduled its 2026 annual meeting of stockholders for June 11, 2026 at 8:30 a.m. Pacific Time at its principal executive offices in Los Angeles, California. Stockholders of record at the close of business on April 17, 2026 will be entitled to receive notice and vote at the meeting.
The company has set 5:00 p.m. Pacific Time on April 12, 2026 as the deadline for receipt of stockholder proposals and director nominations submitted under Section 2.6 of its Amended and Restated Bylaws. Proposals and nominations must be delivered in writing to the Corporate Secretary at Armata’s principal executive offices and must comply with the advance notice provisions in the bylaws.